

Company

August 19, 2020

AIICO

Top-line Up, Bottom-line Down

Premium Income Grew Amid Lockdown

AIICO Insurance Plc. (AIICO) grew gross premium income (GPI) by 24.31% YoY to NGN29.07bn in H1:2020 (vs. NGN23.39bn in H1:2019). The Life segment of the business was the main driver of growth, with premium income from the segment rising by 30.41% YoY in H1:2020, while the non-life business also recorded an improvement of 8.46% to NGN6.21bn. cash premium received during the period rose to NGN31.58bn (vs. 14.05bn in H1:2019), despite the prevailing macroeconomic challenges. For H2:2020, we expect the firm to drive premium income higher, having crossed the recapitalization hurdle and the resulting increase in underwriting capacity. Thus, we have revised our growth expectation for premium income upward from 10.00% to 14.56% by FY2020.

Underwriting Performance Worsens due to Provisioning

Net claims rose by 17.34% YoY to NGN14.45bn (vs. 12.32bn in H1:2019), slower than the growth in premium income. Hence, the loss ratio for the period improved to 56.05% (vs. 59.79% in H1:2019). An indication that the rise (+24.31% YoY) in premium income in the period outpowered the increase (+17.34 YoY) in claims and benefit incurred. The life business continues to account for the most part of claims and benefit, at 88.56% of the total incurred in the period. Underwriting expenses grew by 9.33% YoY to NGN3.43bn (vs. NGN3.14bn in H1:2019), as acquisition and maintenance expenses inched up by 5.60% and 30.71% respectively. This and the increase in provisions for life business to 19.82bn (vs. 11.58bn in H1:2019) worsened the combined ratio to 143.65% (vs. 128.37% in H1:2019). Thus, the underwriting segment recorded a loss of NGN10.86bn (vs. loss of NGN5.65bn in H1:2019).

Growth in Operating Expenses Dims Earnings

Investment income in H1:2020 grew by 44.92% YoY to NGN7.58bn, from NGN5.23bn in H1:2019. This is in line with the 43.12% YoY increase in financial assets to NGN195.95bn (vs. NGN136.91bn H1:2019). However, investment yield remained flattish at 3.87% (vs. 3.82% in H1:2019) in the period – proof of the low yield environment. Management and other operating expenses however grew sharply by 52.96% YoY to NGN6.50bn (vs. NGN4.25bn in H1:2019), moderating the net income by 2.18% to NGN2.79bn, which implies a net margin of 9.59% (vs. 12.19% in H1:2019). For FY2020, we expect profit after tax to moderate further to NGN5.10bn (vs. NGN5.98bn in FY2019) due to rising management and underwriting costs.


Stronger Balance Sheet, Better Future

In Q2:2020, AllCO's capital base improved by NGN0.54bn to NGN19.78bn (Paid-up capital: NGN5.67bn, Share Premium: NGN5.83bn and Retained Earnings: NGN8.29bn). This further strengthened the base beyond the NGN18.00bn regulatory minimum. Likewise, AllCO has recognized NGN1.37bn as available for sale financial asset from the proposed disposal of the firm's 70% stake in AllCO pensions (subject to regulatory approval) to FCMB pensions. When fully implemented, this we expect would give more room for the firm to double down on the core insurance business. Furthermore, the company restructured its financial assets as at H1:2020, lowering the proportion of financial assets valued at amortized cost (held to maturity) from 35.37% in H1:2019 to 27.31%. This should support the active management of its investment portfolio against the widening negative real rate of return.

Recommendation

For FY2020, we estimate AIICO's earnings per share to come in at NGN0.45 and price-earnings ratio at 2.20x, hence, a target price of NGN0.99. This coupled with the current stock price at NGN0.93, portends an upside potential of 6.45%. Thus, we recommend the ticker as a **HOLD**

Company	AllCO
Valuation	
Trailing EPS	0.52
BVPS	2.79
P/E	1.72x
P/BV	0.32x
Target PE	2.20x
Dec-2020 Exp. EPS	0.45
Dec 2020 Target price	0.99
Current Price	0.93
Up/Downside Potential	+6.45%
Ratings	HOLD
Key metrics	
ROE	19.32%
ROA	3.08%
Combined Ratio	143.65%
Loss Ratio	56.05%
Yr High	0.99
Yr Low	0.56
YTD return	-8.25%
Beta	0.46
Adjusted Beta	0.67
52-Week Avg. Volume	3,087,534
Shares outstanding	11.33bn
Market cap [NGN]	10.99bn
Financial year end	December
Most Recent Period (MRP)	H1:2020
. ,	





August 19, 2020

Chart 1: Sensitivity Analysis

Sensitivity Analysis of Dec-2020 Target Price to key model inputs					Min	0.90		
				EPS			Max	1.08
		0.43	0.44	0.45	0.46	0.47	_	
Toward DE	2.10x	0.90	0.92	0.95	0.97	0.99	_	
	2.15x	0.92	0.95	0.97	0.99	2.70		
Target PE	2.20x	0.95	0.97	0.99	1.01	3.85		
	2.25x	0.97	0.99	1.01	1.04	5.01		
	2.30x	0.99	1.01	1.04	1.06	1.08	_	

Financial Highlights (NGN'bn) AIICO INSURANCE PLC H1	:2020		
Profit & Loss Account	H1:2020	H1:2019	y/y Growth
Gross Premium Written	31.92	25.42	25.57%
Gross Premium Earned	29.07	23.39	24.31%
Re-Insurance Costs	3.28	2.78	18.04%
Net Premium Earned	25.79	20.60	25.16%
Fees and Commission Income	1.06	0.79	33.44%
Claims Incurred	14.45	12.32	17.34%
Underwriting Expenses	3.43	3.14	9.33%
Underwriting Profit	-10.86	-5.65	92.27%
Investment Income & Other income	7.58	5.23	44.92%
Other Income	11.95	7.68	55.56%
OPEX	6.50	4.25	52.96%
PBT	2.17	3.02	-27.97%
PAT	2.79	2.85	-2.18%
Balance Sheet	H1:2020	2019FY	y/y Growth
Cash and bank balances	12.87	10.08	27.64%
Financial Assets	183.08	126.83	44.35%
Trade, other Receivables & Prepayments	2.57	6.61	-61.10%
Reinsurance assets	8.48	5.46	55.24%
Investment properties	0.77	0.77	0.00%
Fixed Assets	7.45	7.60	-1.92%
Other Assets	4.46	2.12	109.97%
Total Assets	219.68	159.48	37.75%
Insurance contract liabilities	106.91	84.99	25.80%
Investment contract liabilities	19.31	16.20	19.17%
Trade payables	1.38	1.84	-24.91%
Other payables and Provisions	11.47	3.65	214.16%
	48.99	23.89	105.06%
Other Liabilities	40.55		
Other Liabilities Total Liabilities	188.06	130.57	44.03%



August 19, 2020

Contact Information

Brokerage and Retail Services

topeoludimu@meristemng.com abisoyeoludipe@meristemng.com contact@meristemng.com (+234 905 569 0627) (+234 708 000 7861)

Investment Banking/Corporate Finance

seunlijofi@meristemng.com

(+234 808 536 5766)

Wealth Management

damilolahassan@meristemng.com www.meristemwealth.com Tel: +234 01 738 9948 (+234 803 613 9123)

Registrars

muboolasoko@meristemregistrars.com martinaosague@meristemregistrars.com www.meristemregistrars.com (+234 803 324 7996) (+234 802 303 1783)

Tel: +23401-280 9250

Group Business Development

saheedbashir@mersitemng.com ifeomaogalue@meristemng.com

(+234 802 454 6575) (+234 802 3942967)

Client Services

blessingogwuche@meristemng.com

(+234 706 896 5173)

Investment Research

ahmedjinad@meristemng.com research@meristemng.com

(+234 809 183 9487)

Corporate websites:

www.meristemng.com

www.meristemwealth.com

www.meristemregistrars.com

Meristem Research can also be accessed on the following platforms:

Meristem Research portal: meristem.com.ng/rhub

Bloomberg: MERI <GO> **Capital IQ:** www.capitaliq.com

ISI Emerging Markets: www.securities.com/ch.html?pc=NG

Reuters: www.thomsonreuters.com

FactSet: www.factset.com



August 19, 2020

Analyst's Certification and Disclaimer

This research report has been prepared by the research analyst(s), whose name(s) appear(s) on the cover of this report. Each research analyst hereby certifies, with respect to each security or issuer covers in this research that:

- (1) all of the views expressed in this report accurately reflect his or her personal views about any and all of the subject securities or issuers (the Issuer); and
- (2) no part of any of the research analyst's compensation was, is, or will be directly or indirectly related to the specific recommendations or views expressed by the research analyst(s) in this report. Research analysts' compensation is determined based upon activities and services intended to benefit the investor clients of Meristem Securities Limited (the Firm). Like all of the Firm's employees, research analysts receive compensation that is impacted by overall Firm profitability, which includes revenues from other business units within the Firm.
- (3) each research analyst and/or persons connected with any research analyst may have interacted with sales and trading personnel, or similar, for the purpose of gathering, synthesizing and interpreting non-material non-public or material public market information.

As at the date of this report, any ratings, forecasts, estimates, opinions or views herein constitute a judgment, and are not connected to research analysts' compensations. In the case of non-currency of the date of this report, the views and contents may not reflect the research analysts' current thinking. This document has been produced independently of the Issuer. While all reasonable care has been taken to ensure that the facts stated herein are accurate and that the ratings, forecasts, estimates, opinions and views contained herein are fair and reasonable, neither the research analysts, the Issuer, nor any of its directors, officers or employees, shall be in any way responsible for the contents hereof, and no reliance should be placed on the accuracy, fairness or completeness of the information contained in this document. No person accepts any liability whatsoever for any loss howsoever arising from any use of this document or its contents or otherwise arising in connection therewith.

Analysts' Compensation: The equity research analysts responsible for the preparation of this report receive compensation based upon various factors, including the quality and accuracy of research, client feedback, competitive factors, and overall firm revenues, which include revenues from, among other business units, Investment Banking.

Investment Ratings

Fair Value Estimate

We estimate stock's fair value by computing a weighted average of projected prices derived from discounted cash flow and relative valuation methodologies. The choice of relative valuation methodology (ies) usually depends on the firm's peculiar business model and what in the opinion of our analyst is considered as a key driver of the stock's value from a firm specific as well as an industry perspective. However, we attach the most weight to discounted cash flow valuation methodology.

Target Price Estimate

While we believe that the fair value is underpinned by the future benefits stream and growth outlooks, which are primary drivers of value, the market might not align to the fair value estimate within the estimated investment horizon. Thus, we do not derive our target price from the fair value but from a trading perspective using the year projected earnings or book value and the respective target multiples. Notwithstanding, we are of the opinion that the variance between the two should not be too significant.

Ratings Specification

BUY: Target Price of the stock is above the current market price by at least 10 percent

HOLD: Target Price of the stock ranges between **-10 percent and 10 percent** from the current market price.

SELL: Target Price of the stock is more than **10 percent** below the current market price.



August 19, 2020

Definitions

Price Targets: Price targets reflect in part the analyst's estimates for the company's earnings. The achievement of any price target may be impeded by general market and macroeconomic trends, and by other risks related to the company or market and may not occur if the company's earnings fall short of estimates.

Asset allocation: The recommended weighting for equities, cash and fixed income instrument is based on a number of metrics and does not relate to a particular size change in one variable.

Movements in Price Target

Company Name: AIICO Insurance Plc.

Date	Price (N)	Previous Target Price(N)	New Target Price (N)	Previous Recommendation	New Recommendation
06-May-20	0.97	0.94	1.96	HOLD	BUY
19-Aug-20	0.93	1.96	0.99	BUY	HOLD

Company disclosures

Meristem or the analyst(s) responsible for the coverage may have financial or beneficial interest in securities or related investments discussed in this report, which could, unintentionally, affect the objectivity of this report. Material interests, which Meristem or the analyst(s) have with companies or in securities discussed in this report, are disclosed below:

	F: 1
Company	Disclosure
AIICO Insurance Plc.	

- a. The analyst(s) hold(s) personal positions (directly or indirectly) in a class of the common equity securities of the company.
- b. The analyst responsible for this report, as indicated on the front page, is a board member, officer or director of the company
- c. Meristem beneficially owns 1% or more of the equity securities of the company
- d. Meristem has been the lead manager or co-lead manager of any publicly disclosed offer of securities of the company over the past 12 months.
- e. Meristem beneficially holds a major interest in the debt of the company
- f. Meristem has received compensation for investment banking activities from the company within the last 12 months
- g. Meristem intends to seek, or anticipates receipt of compensation for investment banking services from the company in the next 3 months
- h. The content of this research report has been communicated with the company, following which this research has been materially amended before its distribution
- i. The company is a client of the stock broking division of the Meristem group.
- j. The company is a client of the investment banking division of the Meristem group.
- k. Meristem is the registrar to the company.
- 1. The company owns more than 5% of the issued share capital of Meristem
- m. Meristem has other financial or other material interest in the company.



August 19, 2020

Conflict of Interest

It is the policy of Meristem Securities Limited and its subsidiaries and affiliates (Individually and collectively referred to as "Meristem") that research analysts may not be involved in activities that suggest that they are representing the interests of Meristem in a way likely to appear to be inconsistent with providing independent investment research. In addition, research analysts' reporting lines are structured so as to avoid any conflict of interests.

For example, research analysts are not subject to the supervision or control of anyone in Meristem's Investment Banking or Sales and trading departments. However, such sales and trading departments may trade, as principal, on the basis of the research analysts' published research. Therefore, the proprietary interests of those Sales and Trading departments may conflict with your interests.

Important Disclosure

For U.S. persons only: This research report is a product of Meristem Securities, which is the employer of the research analysts who has prepared the research report. The research analysts preparing the research report are resident outside the United States (U.S.) and are not associated persons of any U.S. regulated broker-dealer and therefore the analysts are not subject to supervision by a U.S. broker-dealer, and are not required to satisfy the regulatory licensing requirements of FINRA or required to otherwise comply with U.S. rules or regulations regarding, among other things, communications with a subject company, public appearances and trading securities held by a research analyst account.

This report is intended for distribution by Meristem Securities only to "Major Institutional Investors" as defined by Rule 15a-6(b)(4) of the U.S. Securities and Exchange Act, 1934 (the Exchange Act) and interpretations thereof by U.S. Securities and Exchange Commission (SEC) in reliance on Rule 15a 6(a)(2). If the recipient of this report is not a Major Institutional Investor as specified above, then it should not act upon this report and return the same to the sender. Further, this report may not be copied, duplicated and/or transmitted onward to any U.S. person, which is not the Major Institutional Investor.

Legal entity disclosures

Meristem Securities Limited is a member of The Nigerian Stock Exchange and is authorized and regulated by the Securities and Exchange Commission to conduct investment banking and financial advisory business in Nigeria. However, the company through its subsidiaries carries out stock broking, wealth management, trustees and registrars businesses which are regulated by the SEC and ICMR.

Copyright 2020 Meristem Securities Limited. All rights reserved. This report or any portion hereof may not be reprinted, sold or redistributed without the written consent of Meristem Securities Limited.